Temozolomide Side Effects
Some side effects of temozolomide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to temozolomide: oral capsule
Get emergency medical help if you have any of these signs of an allergic reaction while taking temozolomide: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
-
seizure (convulsions);
-
numbness or tingling on one side of your body;
-
signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, unusual weakness;
-
dry cough, feeling short of breath, weight loss, night sweats;
-
pain or burning when you urinate;
-
white patches or sores inside your mouth or on your lips; or
-
nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects of temozolomide may include:
-
hair loss;
-
tired feeling;
-
diarrhea, constipation;
-
mild skin rash;
-
dizziness, blurred vision;
-
sleep problems (insomnia); or
-
unusual or unpleasant taste in your mouth.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to temozolomide: intravenous powder for injection, oral capsule
Gastrointestinal
Gastrointestinal effects including nausea (53%), vomiting (42%), constipation (33%), diarrhea (16%), abdominal pain (9%), and anorexia (9%) have been reported.
General
General effects including headache (41%), fatigue (34%), asthenia (13%), fever (13%), and back pain (8%) have been reported.
Nervous system
Nervous system effects including convulsions (23%), hemiparesis (18%), dizziness (12%), abnormal coordination (11%) amnesia (10%), insomnia (10%), paresthesia (9%), somnolence (9%), paresis (8%), urinary incontinence (8%), ataxia (8%), dysphasia (7%), local convulsions (6%), abnormal gait (6%), and confusion (5%) have been reported.
Cardiovascular
Cardiovascular effects including peripheral edema (11%) have been reported.
Other
Other effects including viral infection (11%) have been reported.
Endocrine
Endocrine effects including adrenal hypercorticism (8%) have been reported.
Genitourinary
Genitourinary effects including urinary tract infection (8%), increased frequency of micturition (6%) and female breast pain (6%) have been reported.
Respiratory
Respiratory effects including upper respiratory tract infection (8%), pharyngitis (8%), sinusitis (6%), and coughing (5%) have been reported. Cases of interstitial pneumonitis/pneumonitis, alveolitis, and pulmonary fibrosis have been reported.
Dermatologic
Dermatologic effects including rash (8%) and pruritus (8%) have been reported.
A case of diffuse erythematous skin rash that progressed to an extensive full body desquamative skin rash has been reported. Even though temozolomide was permanently discontinued, the patient continued to experience the rash on a long-term basis with periodic exacerbations.
Psychiatric
Psychiatric effects including anxiety (7%) and depression (6%) have been reported.
Metabolic
Metabolic effects including weight gain (5%) have been reported.
Musculoskeletal
Musculoskeletal effects including myalgia (5%) have been reported.
Ocular
Ocular effects including diplopia (5%) and abnormal vision (5%) have been reported.
Immunologic
Immunologic side effects including rare cases of opportunistic infections such as Pneumocystis carinii pneumonia have been reported.
Oncologic
Oncologic side effects such as very rare cases of myelodysplastic syndrome and secondary malignancies, including leukemia and newly diagnosed glioblastoma multiforme have been reported.
Hematologic
Hematologic side effects have been reported very rarely including prolonged pancytopenia (which may result in aplastic anemia).
Hepatic
Postmarketing hepatic side effects have included elevated liver enzymes, hyperbillirubinemia, cholestasis, and hepatitis.
More temozolomide resources
- temozolomide MedFacts Consumer Leaflet (Wolters Kluwer)
- temozolomide Advanced Consumer (Micromedex) - Includes Dosage Information
- Temozolomide Professional Patient Advice (Wolters Kluwer)
- Temozolomide Monograph (AHFS DI)
- Temodar Prescribing Information (FDA)
- Temodar Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


